Table 2.
Tolerability (Adherence) to Aerobic Training
| Variable/Reasons | No. of Patients† | %* | No. of Sessions | %* |
|---|---|---|---|---|
| Conventional Variables | ||||
| Lost to follow upNot completing follow-up assessments | 2 | 8 | ||
| Attendance Attended/planned treatments | - | 79 | ||
| Exploratory variables | ||||
| Permanent discontinuation | 6 | 24 | 213 | 12 |
| Health-related | 3 | 12 | 124 | 7 |
| Lower extremity pain | 2 | 8 | 96 | 5 |
| Other | 1 | 4 | 28 | 2 |
| Non health-related | 3 | 12 | 89 | 5 |
| Motivational | 3 | 12 | 89 | 5 |
| Treatment interruption | 11 | 44 | 81 | 4 |
| Health-related | 2 | 8 | 8 | 1 |
| Lower extremity pain | 1 | 4 | 5 | 1 |
| Dental | 1 | 4 | 3 | 1 |
| Non health-related | 9 | 36 | 73 | 4 |
| Vacation | 6 | 24 | 54 | 3 |
| Not known | 3 | 12 | 19 | 1 |
| Dose modification‡ | 24 | 96 | 135 | 7 |
| Health-related | 24 | 96 | 130 | 7 |
| General exercise-related events | 16 | 66 | 58 | 3 |
| Severe fatigue | 8 | 33 | 27 | 2 |
| Lower extremity pain | 10 | 40 | 40 | 1 |
| Muscle strain | 1 | 4 | 1 | <1 |
| Nausea | 1 | 4 | 2 | <1 |
| Allergic reaction | 1 | 4 | 1 | <1 |
| Gastrointestinal-related | 1 | 4 | 1 | <1 |
| Non health-related | 2 | 8 | 5 | 1 |
| Not known | 2 | 8 | 5 | 1 |
| Pre-treatment intensity modification | 14 | 56 | 33 | 2 |
| Not known | 14 | 56 | 33 | 2 |
| Early session termination‡ | 18 | 72 | 59 | 3 |
| Health-related | 24 | 96 | 55 | 3 |
| General exercise-related events | 15 | 62 | 42 | 2 |
| Lower extremity pain | 3 | 12 | 4 | <1 |
| Excessive fatigue | 2 | 8 | 5 | <1 |
| Gastrointestinal | 1 | 4 | 1 | <1 |
| Headache | 1 | 4 | 1 | <1 |
| Nausea | 1 | 4 | 1 | <1 |
| Dizziness | 1 | 4 | 1 | <1 |
| Non health-related | 4 | 16 | 4 | <1 |
| Time constraints | 3 | 12 | 3 | <1 |
| Not known | 1 | 4 | 1 | <1 |
Definitions: permanent discontinuation: permanent discontinuation of treatment prior to week 24; dose interruption: missing ≥3 consecutive supervised treatments; dose modification: ≥1 treatment required dose modification, and the total number of treatments requiring a dose reduction; treatment dose intensity resequence: intensity of ≥1 treatment session required modification; and early session termination: ≥1 aerobic training sessions required early termination.
All variables are collectively counted as one entity in the same patient unless otherwise indicated.
Numbers may not add up to 100% in each section due to rounding.
Number of reasons for dose modification sums to greater than the total number of patients listed since several patients required dose modification for different reasons.